Actively Recruiting
Evaluating Safety, Tolerability, and Pharmacokinetics of AG-181 in Adults with Phenylketonuria
Led by Agios Pharmaceuticals, Inc. · Updated on 2026-10-28
20
Participants Needed
5
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of AG-181 in adults with Phenylketonuria PKU, a genetic condition affecting metabolism. This Phase 1b, open-label study aims to understand how the drug behaves in the body and its effects on phenylalanine levels. The trial is sponsored by Agios Pharmaceuticals, Inc. and focuses on assessing adverse events and pharmacokinetics. Participants will receive AG-181 film-coated tablets daily from Day 1 to Day 28. The study includes two cohorts, both receiving the investigational drug without any placebo comparison. The treatment period is followed by monitoring for safety and drug concentration up to Day 42. The study does not involve randomization or blinding. During the study, participants will undergo regular evaluations including blood tests to measure drug levels and phenylalanine concentration. Researchers will monitor adverse events and serious adverse events related to the study drug up to 42 days. The total duration of participation covers treatment and follow-up assessments to gather comprehensive safety and pharmacodynamics data.
CONDITIONS
Brief Title
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
Research Team
A
Agios Medical Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here